ClinicalTrials.gg
Active, not recruitingNCT05471544Updated Mar 25, 2024

Effectiveness, Feasibility and Acceptability of Seasonal Malaria Chemoprevention in Aweil South County in South Sudan

A Phase 3 interventional study of Sulfadoxine pyrimethamine and Amodiaquine in Malaria, sponsored by Malaria Consortium. Active, not recruiting at 1 site in South Sudan. Open to participants aged 3 Months to 59 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-25.

Sponsored by Malaria Consortium · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,575
Allocation
Non-randomized
Ages
3 Months to 59 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies testing amodiaquine in Malaria — 2 open to participants now, 5 under way, 2 of them phase 3. Amodiaquine · Malaria.

Planned enrollment
7th of 44
3,575 · median 738
Started
2022
with 3 others
Phase 3
16 of 46
1 open now
Registered
42nd of 46
by date
Lead sponsor
4 of 46
Malaria Consortium

Among the 46 studies testing amodiaquine in Malaria, this one is the 7th largest by planned enrollment of the 44 interventional ones that give a count, is one of 4 that started in 2022, is one of 16 in phase 3, and was the 42nd registered.

Malaria

1,187 studies on the registry are indexed under Malaria; 80 are open to participants now.

Browse Malaria studies →

Open to participants now

2 of the 46 studies testing amodiaquine in Malaria are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About amodiaquine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 51 Malaria studies recruiting now, 15 (29%) set no upper age limit and 33 (65%) stop at 75 or younger; 37 take children under 18; 31 take healthy volunteers.

This study: 3 Months to 59 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing amodiaquine in Malaria, or all of them as a file.
02

Study summary

This study aims to explore whether SMC is an effective intervention in the context of Northen Bahr el Gazal state, South Sudan. It also aims to assess the protective efficacy of the antimalarials used in SMC in the target population and investigate levels of parasite resistance in the study counties. If successful, this trial should provide the evidence for SMC to be included in malaria programming and policy in South Sudan.

A Type II hybrid effectiveness-implementation study design will be used to evaluate the effects of a clinical intervention on relevant outcomes whilst collecting information on implementation. It is designed to determine feasibility and effectiveness of an innovative intervention, as well as the protective efficacy of the antimalarial drugs used. The study consists of five components: 1) A series of cross-sectional surveys establishing confirmed malaria cases in children; 2) A prospective cohort study to determine the protective efficacy of SPAQ (if SPAQ provides 28 days of protection from infection) and whether drug concentrations and/or resistance influence the duration of protection; 3) A resistance markers study in children 3-59 months in the research county; 4) Modelling the protective effect of SPAQ in South Sudan to determine where SMC could be a suitable malaria prevention strategy in other areas of the country, and 5) A process evaluation to understand feasibility and acceptability of the SMC intervention in South Sudan.

Read the detailed description

This is an implementation research study, using a Type II hybrid effectiveness-implementation study design, to evaluate the effects of a clinical intervention on relevant outcomes whilst collecting information on implementation.

The study uses pragmatic implementation research with the objective of contributing to the development of practical recommendations for health policy, practice and potential scale up. It is designed as an implementation study to determine effectiveness and protective efficacy to gather evidence of its potential impact on health outcomes. Five monthly cycles of SMC will be implemented between June and October 2022 in one county, Aweil South, in Northern Bahr el Gazal state.

The study will comprise the following six components :

  1. Two cross-sectional surveys at the height of the malaria season to explore impact on malaria incidence
  2. End-of-round survey
  3. Prospective protective efficacy cohort study to determine if SPAQ provides 28 days of protection from infection and whether drug concentrations and/or resistance influence the duration of protection
  4. Resistance markers study in children 3-59 months in the two research counties plus the two standard intervention counties to measure changes in resistance marker prevalence over time (pre and post within the same year and between years)
03

Conditions studied

  • Malaria

Browse trials for

Keywords

  • seasonal-malaria-chemoprevention
04

Who can participate

Ages eligible
3 Months to 59 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Being resident in the project area
  • Afebrile with no other malaria associated symptoms in the past 48 hours or at time of recruitment
  • Consent to participate in the study obtained
  • Can comply with 3 day DOT of standard SPAQ regimen (day 0-2)
  • Willingness and ability of the childs guardians to comply with the study protocol for the duration of the study including all dry blood spot and slide collections

Exclusion criteria

Exclusion Criteria:

  • Symptoms of malaria (tympanic fever ≥ 37.5 °C or history of fever in past 48 hours)
  • Known allergy to medicine provided
  • Receiving a sulfa-based medication for treatment or prophylaxis, including co-trimoxazole (trimethoprim-sulfamethoxazole).
  • Individuals receiving azithromycin due to the antimalarial activity of azithromycin.
  • Severe malnutrition according to WHO guidelines
  • Recruited in cross sectional surveys or any other SMC studies.
  • Children with
  • Previous treatment with Amodiaquine in the past 28 days (treatment with ASAQ or SPAQ)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3,575 participants (estimated)

Study arms

  • Experimental
    Sulfadoxine-Pyrimethamine + Amodiaquine (SPAQ)

    Children aged 3-59 months will receive SPAQ in the intervention arm

    Drug: Sulfadoxine pyrimethamine · Drug: Amodiaquine

  • No intervention
    Control

    Children aged 3-59 months will not receive SPAQ in the control arm

Interventions

  • DrugSulfadoxine pyrimethamine

    Sulphadoxine is a slowly eliminated sulphonamide. It is used in a fixed dose combination of 20 parts sulphadoxine with 1 part pyrimethamine given orally or intramuscularly. The medicine is no longer recommended for the treatment of malaria. However, it is being used for Intermittent Preventive Treatment during pregnancy (IPTp) and as a co-packaged combination with amodiaquine for seasonal malaria chemoprevention. Sulphadoxine is readily absorbed from the GIT. It is widely distributed in body tissues and fluids and crosses the placenta into foetal circulation. It is also readily detectable in breast milk. It is excreted predominantly as the unchanged drug.

    Also known as: SP

  • Amodiaquine is a Mannich base 4 amino-quinoline that interferes with parasite haem detoxification. It is more effective than chloroquine in both chloroquine sensitive and resistant P. falciparum infections. However, there is cross-resistance between chloroquine and amodiaquine. It is readily absorbed in the GIT and rapidly converted in the liver to the active metabolite, desethylamodiaquine. Desethylamodiaquine is responsible for all the antimalarial effect.

    Also known as: AQ

06

What researchers measure

Primary outcomes

  1. Malaria incidence in study population in intervention county and eligible children in one control county

    Number of malaria cases in the intervention population and eligible children in one control county over the study period as reported through care givers in cross-sectional surveys at baseline, mid-intervention and endline

    Time frame: Five months

  2. Chemoprevention failure as defined by positive parasites in malaria slides after day 7 or positive qPCR in dried blood spot (DBS) on day 28

    Malaria slides and dry blood spots (DBS) taken at days 0,7, 28 will be analysed with qPCR methodology to detect low level submicroscopic parasitemia in children treated with SPAQ

    Time frame: One month

  3. Prevalence of antimalarial resistance markers (dhfr, dhps, Pfcrt, pfmdr1) among chemoprevention failures as defined in outcome 2

    All Dried blood spots (DBS) will be analysed for malaria mutation genotypes (dhfr, dhps, Pfcrt, pfmdr1) on baseline and endline and additionally on day 7, day 28, or if participant slide is positive for parasites on day 7 or an infection is reported through care givers in cross-sectional survey.

    Time frame: One month

  4. Drug concentrations of Sulfadoxine-pyrimethamine and amodiaquine among chemoprevention failures (as defined in outcome 1)

    Drug concentrations will be analyzed for all samples on baseline, day 7 and day 28 and will be linked to chemoprevention failure cases as defined in outcome 2 or a malaria infection is reported through care givers in cross sectional survey.

    Time frame: One month

07

Study locations

1 site
  • Aweil South
    Aweil, Northern Bahr El Gazal, South Sudan
08

References and documents

Individual participant data

Plan to share: No — As this data is sensitive we propose not to share it.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Dec 2024, 28 months after the start.

Of 44 non-industry phase 3 interventional studies under Malaria, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 34. This study's planned 28 months is above that.

Counting every sponsor, half of 50 studies reached it within 23 months; a quarter within 17 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2022
First posted
Jul 25, 2022
StartActual
Jul 18, 2022
Primary completionEst.
Dec 15, 2024
CompletionEst.
Dec 31, 2024
Last update
Mar 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05471544
Lead sponsor
Malaria Consortium
Responsible party
Sponsor
First posted
Jul 25, 2022
Start date
Jul 18, 2022
Primary completion
Dec 15, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Mar 25, 2024

Study contacts

Ahmed Ismail Julla
principal investigator · Ministry of Health, South Sudan

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amodiaquine

Start the discussion